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Dapsone exhibits activity against Mycobacterium tuberculosis and Mycobacterium avium com-
plex (MAC) in vitro. We retrospectively examined the incidence of mycobacterial diseases within
a randomized prospective trial of prophylaxis for Pneumocystis carinii pneumonia and toxoplas-
mosis. Of 501 participants who had not previously had a mycobacterial disease, 274 received
dapsone/pyrimethamine (200/75 mg once weekly) and 227 received aerosolized pentamidine
(300 mg once every 4 weeks). The median CD4 lymphocyte count was 113/AL, and the median
duration of treatment was 369 days. Six cases of tuberculosis, 22 of MAC infection, and 3 of
Mycobacterium genavense disease occurred during treatment. Stratified by baseline CD4 lym-
phocyte counts, the annual product-limit incidence of mycobacterial disease was 5% during
treatment with dapsone/pyrimethamine vs. 12% during treatment with aerosolized pentamidine
for patients whose counts were 0-24/AL, 0 vs. 12% for those whose counts were 25-49/AL, and
7% vs. 9% for those whose counts were 50-99/AL. Adjusted for CD4 lymphocyte counts at start
of treatment, the relative risk for patients receiving dapsone/pyrimethamine was 0.47 (95%
confidence interval, 0.19-1.16; P = .10). This inexpensive and simple regimen may prevent
mycobacterial diseases and warrants further investigation as a means of prophylaxis for multiple
opportunistic diseases.
The risk of tuberculosis for human immunodeficiency
virus (HIV)—infected patients is > 100-times that for the gen-
eral population [ 1 ]. In the presence of severe immune defi-
ciency, however, nontuberculous mycobacterioses—mainly
Mycobacterium avium complex (MAC) disease—become
predominant [2]. In fact, the annual incidence of MAC bac-
teremia was as high as 20% in a study of patients with AIDS
and CD4 lymphocyte counts of 20-39/AL [3]. Hence, pro-
phylaxis for mycobacterial diseases in immunosuppressed,
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HIV-infected patients is generating increased interest. Based
on the results of two prospective studies [2], a recommenda-
tion has recently been issued that rifabutin be used as pro-
phylaxis for MAC disease in patients with CD4 lymphocyte
counts of <100/AL [4]. Despite the proven antimycobacter-
ial activity of numerous other agents, no controlled data exist
concerning their prophylactic efficacy.
We conducted a prospective, randomized trial comparing
dapsone/pyrimethamine (200/75 mg once weekly) with aer-
osolized pentamidine (300 mg once every 4 weeks) as pro-
phylaxis for Pneumocystis carinii pneumonia (PCP) and toxo-
plasmic encephalitis [5]. Dapsone is active against
Mycobacterium tuberculosis and MAC in vitro [6, 7] and may
have prophylactic efficacy against MAC in HIV-infected pa-
tients [8]. We therefore decided to retrospectively examine
the incidence of tuberculous and nontuberculous mycobacte-
rial diseases in participants of our study to assess the prophy-
lactic efficacy of dapsone/pyrimethamine in comparison
with that of aerosolized pentamidine.
Methods
Study Population
The participants were adults with symptomatic HIV infec-
tion and/or <200 CD4 lymphocytes per AL. Persons were
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not disqualified if they had previously had PCP or had re-
ceived prophylaxis with aerosolized pentamidine, and simul-
taneous antiretroviral treatment was allowed. Exclusion crite-
ria were prior toxoplasmic encephalitis, current treatment
with drugs active against P. carinii or Toxoplasma gondii,
pregnancy, active iv drug use, and a serum creatinine level
> 120 Amol/L. An additional exclusion criterion for the pres-
ent analysis was the occurrence of mycobacterial infection
prior to randomization. The study design was approved by
the ethics committees of the participating hospitals, and all
participants gave informed consent.
Study Design
This controlled, open-label trial was conducted in 7
centers in Switzerland, 4 centers in Milan, Italy, and 1 center
in Besancon, France. Participants were assigned by random-
ization to one of two treatment groups to receive either 200
mg of dapsone and 75 mg of pyrimethamine once weekly or
300 mg of aerosolized pentamidine (by means of a Respir-
gard II [Marquest, Englewood, NJ]) every 4 weeks, under the
supervision of a nurse. Block randomization with a 1:1 ratio
was used, and stratification was by center, history of previous
PCP, and positivity or negativity for toxoplasmal IgG. Fo-
linic acid was not routinely administered. The protocol al-
lowed a change from one treatment group to the other in
cases of intolerance or occurrence of breakthrough PCP. For
the last 28% of participants enrolled in the study, the random-
ization ratio was changed to 2:1 in favor of the dapsone/
pyrimethamine regimen to compensate for a high rate of
switches to treatment with aerosolized pentamidine.
The participants were evaluated every 4 weeks during
treatment, or until the study ended on 31 December 1992,
for symptoms, opportunistic infections, compliance, adverse
events, and laboratory data. Routine mycobacterial cultures
were not performed for asymptomatic patients.
The present retrospective subanalysis of the trial focused
on the incidence of mycobacterial diseases. Participants with
known disease or colonization with M. tuberculosis, MAC, or
other pathogenic mycobacteria prior to randomization were
excluded from this analysis. The endpoints were diagnosis of
tuberculous or nontuberculous mycobacterial disease, as de-
fined by the occurrence of symptoms (such as fever, night
sweats, and/or weight loss) that mandated a diagnostic
workup, the detection of pathogenic mycobacteria in the re-
spective organ(s), and—in cases of localized nontuberculous
disease—the response to antimycobacterial treatment. One
patient with pulmonary colonization due to MAC whose
blood cultures were repeatedly negative was not considered
for this analysis. The occurrence of mycobacterial diseases
was evaluated in relation to treatment actually received; ob-
servation ended 30 days after the stop of the respective treat-
ment. Patients who switched treatment groups were evalu-
ated during the actual duration of each treatment, and CD4
Table 1. Baseline characteristics of the 501 participants in the
study, who were assigned by randomization to one of two treatment
groups.
Characteristic
Treatment group
DP
(n = 274)
AP
(n = 227)
Age (y), mean 36 35
Male (%) 83 84
Homosexual or bisexual (%) 43 35
Injection drug use (%) 34 39
Previous CDC stage IVC1 infection* (%) 27 27
Previous use of zidovudine or
didanosine (%) 90 91
CD4 lymphocytes per AL,
median no. (range) 117(1 -610) 106(1 -530)
NOTE. DP = dapsone/pyrimethamine: AP = aerosolized pentamidine.
None of the parameters differed significantly between the two treatment
groups.
* i.e., a previous AIDS-defining opportunistic infection (CDC = Centers
for Disease Control and Prevention).
lymphocyte counts at the time of the switch were considered
the baseline value for the second treatment.
Statistical Analysis
Baseline characteristics were compared by means of the x 2
test or the Mann-Whitney test, as appropriate. Intraindivi-
dual changes in CD4 lymphocyte counts were compared by
the Wilcoxon signed-rank test. The probability of remaining
free of mycobacterial disease was calculated by means of the
Kaplan-Meier life-table analysis. Multivariate Cox (propor-
tional hazards) regression analysis was used to estimate fac-
tors predictive of mycobacterial disease; the relative risk in
patients treated with dapsone/pyrimethamine was adjusted
for CD4 lymphocyte counts at start of treatment. A P value
of <.05 was considered statistically significant.
Results
Patients' Characteristics
A total of 533 patients were randomly assigned to treat-
ment. Thirty-two had a previously diagnosed mycobacterial
disease and were therefore excluded from the present analy-
sis; nine had nontuberculous mycobacteriosis, and 23 had
tuberculosis. The remaining 501 participants were not re-
ceiving any drugs with antimycobacterial activity at the time
of randomization and could therefore be evaluated for occur-
rence of mycobacterial disease during the study. Of these 501
patients, 274 were assigned to the dapsone/pyrimethamine
treatment group and 227 to the aerosolized pentamidine
treatment group.
The baseline characteristics of the two groups were well
balanced (table 1); the average age was 35.5 years, 83% were
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Table 2. Mycobacterial diseases that occurred during the study in 31 of the participants.
Disease Site of detection
Mycobacterium
species implicated
No. of participants
infected
Systemic Blood, bone marrow MAC 21
M. genavense 2
M. tuberculosis 2
M. africanum 1*
Localized
Pneumonia Sputum, bronchoalveolar
lavage fluid
M. tuberculosis
MAC
2
Meningitis CSF M. tuberculosis
Lymph node abscess Lymph node aspirate M. genavense
* This was counted as one of the six cases of tuberculosis.
male, and the main risk factors for HIV infection were homo-
sexuality (39%) and injection drug use (37%). For the entire
population, the median CD4 lymphocyte count was 113/pl.
Only 27% had had an AIDS-defining opportunistic infection,
but 90% were receiving antiretroviral treatment at the time of
randomization.
The median duration of study medication was 369 days,
corresponding to 504.5 patient-years of treatment (199.4 for
dapsone/pyrimethamine and 305.1 for aerosolized pentami-
dine). Ninety-nine patients switched from the originally as-
signed treatment group to the other one: 83 because of intol-
erance for dapsone/pyrimethamine, 7 because of intolerance
for aerosolized pentamidine, 6 because of breakthrough PCP
(2 were receiving dapsone/pyrimethamine and 4 were re-
ceiving aerosolized pentamidine), and 3 for other reasons
(e.g., possible but not proven PCP and poor compliance).
The CD4 lymphocyte counts of the 88 patients switching
from dapsone/pyrimethamine to aerosolized pentamidine
were significantly lower at the time of the switch (median,
57.5/AL; P < .005) than at the time of randomization; the
incidence of mycobacterial diseases was therefore adjusted
on the basis of CD4 lymphocyte counts determined at the
start of each treatment.
Mycobacterial Diseases
A total of 31 cases of mycobacterial disease were diag-
nosed during treatment: 6 of tuberculosis (involving 1 pa-
tient receiving dapsone/pyrimethamine and 5 receiving
aerosolized pentamidine), 22 of MAC disease (5, dapsone/
pyrimethamine; 17, aerosolized pentamidine), and 3 of M.
genavense infection (all, aerosolized pentamidine). All pa-
tients were symptomatic; infection was detected by means of
blood or bone marrow cultures and was therefore dissemi-
nated in 26 (84%) of the 31 patients (table 2). Among the 25
patients with MAC or M. genavense infection, all had fever,
72% had weight loss, 56% had night sweats, and 36% had
diarrhea. Sixteen received antimycobacterial treatment for at
least 1 month, and 14 (88%) of them—including the two
with localized disease (pneumonia and lymph node
abscess)—responded favorably with respect to their clinical
symptoms.
Eleven patients had a mycobacterial disease after they
switched from dapsone/pyrimethamine to aerosolized penta-
midine (median number of days after switch, 211; range,
38-464 days) (table 3). Among the 31 patients with myco-
bacterial disease, 18 (58%) had baseline CD4 lymphocyte
counts <100/AL. Among those with such counts, the inci-
dence of mycobacterial disease was 3.1 per 100 patient-years
(95% confidence interval [CI], 0.3-8.8) during treatment
with dapsone/pyrimethamine vs. 11.4 (CI, 6.5-11.7) during
treatment with aerosolized pentamidine.
In a multivariate Cox (proportional hazards) regression
analysis, patients receiving dapsone/pyrimethamine had a
relative risk of 0.47 (95% CI, 0.19-1.16; P = .10) of develop-
ing mycobacterial disease (risk was adjusted for CD4 lym-
phocyte counts at the start of treatment). In an analysis con-
sidering only patients with CD4 lymphocyte counts
<100/4, the adjusted relative risk was 0.30 (95% CI, 0.07-
1.32; P = .11). Because the development of mycobacterial
disease was independently predicted by the CD4 lymphocyte
counts at the start of treatment (P = .021), we stratified the
patients' baseline counts into the ranges of 0-24, 25-49,
50-99, 100-199, and >200/4 and calculated the product
limit incidence of mycobacterial disease within these ranges
at different observation times. In all strata with CD4
lymphocyte counts <200/4, mycobacterial diseases devel-
oped earlier and more frequently in patients receiving aero-
solized pentamidine than in those receiving dapsone/
pyrimethamine (nonsignificant trend; table 4).
Mortality
Seventy-five patients died during treatment or within
30 days of its discontinuation; 27 were receiving dapsone/
pyrimethamine and 48 were receiving aerosolized penta-
midine at the time of death. The rate of death per 100
patient-years was similar: 13.5 for patients receiving dap-
CD4
lymphocytes/AL
No. of patients
observed
Treatment
received 3 mo	 6 mo 9 mo	 12 mo
0 5 ± 4 5 ± 4 5 ± 4
0 0 0 0
0 0 0 7 ± 7
0 0 0 5 ± 3
0 0 0 0
3 ± 2 3 ± 2 9 ± 4 12 ± 5
0 3 ± 3 12 ± 6 12 ± 6
0 4 ± 3 7 ± 4 9 ± 5
0 1 ± 1 3 ± 2 6 ± 3
0 0 0 0
DP
	
0-24
	
43
	
25-49
	
35
	
50-99
	
48
	
100-199
	
94
>200
	
65
AP
	
0-24
	
61
	
25-49
	
42
	
50-99
	
58
	
100-199
	
102
>200
	
52
CID 1995;20 (February)	 Dapsone/Pyrimethamine May Prevent Mycobacterioses	 247
Table 3. The duration of treatment and the clinical characteristics and events during such
treatment for the 501 participants.
Assigned treatment
Treatment
switched to
Variable DP AP DP AP
No. of patients 274 227 11 88
Median duration of treatment (person-years) 191.1 229.1 8.3 76.0
Median no. of CD4 lymphocytes per AL 117 106 119* 57.5*
Development of tuberculosis (no. of patients)t 1 2 0 3
Development of NTM, due to MAC or
M. genavense (no. of patients)t 3 12 2 8
No. of deathst 24 32 3 16
NOTE. DP = dapsone/pyrimethamine; AP = aerosolized pentamidine; NTM = non-tuberculous myco-
bacteriosis.
* At the time of switch.
t During the treatment or within 30 days after that treatment ended.
sone/pyrimethamine and 15.7 for patients receiving aero-
solized pentamidine.
Discussion
The subanalysis of this randomized prophylactic trial
shows a trend toward decreased incidence of mycobacterial
diseases in patients receiving dapsone/pyrimethamine vs.
aerosolized pentamidine. The prophylactic effect was more
pronounced in patients whose CD4 lymphocyte counts were
<100/AL at the start of treatment. Among the mycobacterial
diseases observed during the study, disseminated MAC in-
fection was most frequent, followed by pulmonary and extra-
pulmonary tuberculosis and disease due to M. genavense. All
mycobacterial diseases diagnosed involved patients who
were symptomatic and required an appropriate diagnostic
workup; therefore, the observed reduction in incidence con-
cerned clinically manifested mycobacterial diseases and had
a direct impact on the rate of morbidity among recipients of
dapsone/pyrimethamine. These results support the hypothe-
sis that dapsone/pyrimethamine might have prophylactic ef-
ficacy against mycobacteria; however, the results must be
interpreted with caution, as this study was a retrospective
subanalysis of a prospective trial originally designed to assess
prevention of PCP and toxoplasmosis rather than antimyco-
bacterial efficacy.
Dapsone exhibits in vitro activity against both M. tubercu-
losis and MAC [6, 7], has moderate antituberculous activity
in vivo [9, 10], and has been used as part of a combination
regimen to treat tuberculosis [1 1]. Although dapsone did not
show therapeutic efficacy against murine MAC infection,
prophylactic administration of dapsone was effective in re-
ducing MAC bacteremia and the number of bacteria in dif-
ferent organs in the same model [12]. In a recent retrospec-
tive analysis, dapsone also tended to lower the incidence of
MAC bacteremia in HIV-infected patients [8]. Considering
Table 4. Product limit incidence of mycobacterial disease, stratified by patients' CD4 lymphocyte
counts at the time treatment started.
Incidence (% ± SD)
NOTE. DP = dapsone/pyrimethamine; AP = aerosolized pentamidine.
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the presence of dihydrofolate reductase in mycobacteria [ 13,
14] and its possible inhibition by pyrimethamine, we believe
the combination of dapsone and pyrimethamine theoreti-
cally may have an additive activity against mycobacteria, but
we are not aware of any data reporting the effects of pyri-
methamine on mycobacteria.
The estimated annual incidence of mycobacterial diseases
among patients in our study who were receiving aerosolized
pentamidine and whose baseline CD4 lymphocyte counts
were <50/AL was 12%. This is lower than previously re-
ported data from the United States concerning the incidence
of MAC bacteremia, which indicated the rate was as high as
20% for patients with AIDS and 20-39 CD4 lymphocytes per
AL and even higher with decreasing CD4 lymphocyte counts
[3, 15]. We did not perform routine blood cultures for all our
patients; the diagnostic workup was mandated by symptoms
and signs. The true rate of mycobacterial bacteremia there-
fore may have been underdiagnosed, as indicated by a study
of asymptomatic patients with < 100 CD4 lymphocytes per
AL in whom routine screening detected previously unsus-
pected MAC bacteremia at a rate of 5.9% [16]. A small per-
centage of cases of asymptomatic MAC bacteremia, how-
ever, probably would have affected both treatment groups in
our study equally. The evaluation of the occurrence of myco-
bacterial disease is nonetheless clinically important, as the
ultimate goal of prophylaxis is reduction of morbidity rather
than reduction of bacteremia.
Rifabutin and clarithromycin have been previously shown to
have efficacy in primary prophylaxis for MAC bacteremia in
clinical studies [2, 8]. The combination of clarithromycin and
dapsone prevented experimental murine MAC infection [12]
and may also be effective in humans. Until now, only rifabu-
tin had been evaluated in a controlled trial and reduced the
incidence of MAC bacteremia by 45% in comparison with the
incidence in placebo recipients [2]. However, the cost of these
regimens is considerable, and the cost-benefit ratio is un-
known. Prophylaxis with rifabutin (300 mg once daily) costs
close to $200 per month [4]. On the basis of the local inci-
dence of mycobacterial diseases in patients with < 100 CD4
lymphocytes per AL, the prevention of one case of nontuber-
culous mycobacteriosis in Switzerland would cost >$66,000
per year [17]. With a monthly cost of —$2 [18], dapsone/
pyrimethamine compares favorably with other prophylactic
agents. In addition, dapsone/pyrimethamine is an attractive
alternative because of its potential for once-weekly administra-
tion as well as the fact that it is not used for treatment of
mycobacterioses, so a possible induction of resistance would
not have immediate therapeutic implications.
However, tolerance for dapsone/pyrimethamine in our
study was poor; 30% of participants had to switch to aeroso-
lized pentamidine because of intolerance. The most frequent
reasons for discontinuation of the treatment were nausea,
skin rash, headache, fever, and anemia [5]. The course of the
hypersensitivity reactions was reversible with symptomatic
treatment; no cases of sulfone syndrome [19, 20] or other
severe cutaneous reactions were observed.
Our results confirm the significantly increased risk for the
development of mycobacterial diseases in patients whose
CD4 lymphocyte counts are low and—without regard to the
aspect of cost support the assessment that primary prophy-
laxis for MAC disease would be clinically justified for HIV-
infected patients whose CD4 lymphocyte counts are <100/
AL [4]. Dapsone/pyrimethamine and possibly dapsone alone
have already been shown to prevent toxoplasmic encephali-
tis in addition to being efficacious as prophylaxis for PCP [5,
21, 22]. Because a trend toward decreased incidence of myco-
bacterial diseases was observed in the present analysis, com-
bined prophylaxis for multiple opportunistic diseases with
dapsone/pyrimethamine seems feasible. Future studies will
have to address the issues of efficacy, tolerability, availabil-
ity, and cost-benefit ratio to determine the best prophylactic
regimen for immunodeficient, HIV-infected patients.
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